Thrombotargets Corporation Europe Inagurates New Facilities at the National Biotechnology Center in Madrid, Spain
Published: Feb 01, 2007
The new 2500 square feet laboratory will be operative on the second week of February 2007 and will envisage the future growth of the company for the next three years. CNB offers to Thrombotargets Europe research team a full access to the most advanced facilities, such as proteomic and genomic services, protein design, protein tools, electron microscopy, transgenesis and animal facilities (www.cnb.uam.es). In addition, this agreement will facilitate further interaction of Thrombotargets Europe members with the research activities of one of the most advanced biotech institutes in Europe.
The potential of this new research laboratory in cooperation with tha already existing facilities in Barcelona will provide Thrombotargets the capability to undertake research projects from drug discovery to clinical trials.